表紙:アントラサイクリンの世界市場レポート 2024年
市場調査レポート
商品コード
1415661

アントラサイクリンの世界市場レポート 2024年

Anthracycline Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
アントラサイクリンの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

アントラサイクリン市場規模は近年力強く成長しています。2023年の14億1,000万米ドルから2024年には15億2,000万米ドルへとCAGR7.8%で拡大します。実績期間の成長は、がん有病率の上昇、個別化がん治療に対する需要の高まり、アントラサイクリンの利点に対する意識の高まり、アントラサイクリンへの投資などに起因しています。

アントラサイクリン市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR6.8%で19億7,000万米ドルに成長します。予測期間の成長は、がん治療に対する意識の高まり、がん治療の研究開発への投資、効果的で便利ながん治療への需要の高まり、がん検診プログラムの増加、政府の取り組みなどに起因します。予測期間における主な動向としては、アントラサイクリン製剤の進歩、併用療法、心保護戦略、アントラサイクリンのバイオシミラーの開発などが挙げられます。

急増するがんの有病率は、アントラサイクリン市場の将来の成長の主要な触媒として働くと考えられています。がんは、体内のほぼすべての臓器や組織で発現する可能性のある異常細胞の抑制されない増殖を特徴とする疾患群であり、しばしば典型的な境界を超え、体の他の部分に広がったり、近隣の組織に侵入したりする可能性があります。このような状況において、強力な化学療法薬の一種であるアントラサイクリンは、がん治療において重要な役割を担っています。DNA構造を破壊することで細胞分裂を阻害し、その正常な機能を効果的に停止させることでこれを実現します。例えば、米国を拠点とする非営利医療団体であるAmerican Cancer Society Inc.のデータでは、2023年現在、米国では190万人と推定され、新たながん患者の増加が予測されています。これは、2020年に新たに診断されたがん症例の180万件からの増加です。さらに、2023年のがん関連死亡者数は、2020年の606,520人に比べ、約609,820人になると予想されています。その結果、がんの発生率の増加がアントラサイクリン市場急成長の原動力となっています。

アントラサイクリン市場は予測可能な将来において大幅な成長を遂げる可能性があります。個別化医療は、精密医療とも呼ばれ、個々の患者の特性に合わせた治療アプローチを特徴とする、医療におけるニッチ分野を表しています。このレベルのカスタマイズは、患者の遺伝的、分子的、特異的な疾患特性を考慮に入れ、標的療法と組み合わせたアントラサイクリン化学療法薬の正確な統合を可能にします。例えば、2022年10月現在、米国を拠点とする健康専門ニュース団体STATの報告によると、75,000を超える遺伝子検査製品と300を超える個別化医薬品が存在していることが明らかになった。さらに、米国を拠点とする代表的な組織である個別化医療連合(Personalized Medicine Coalition)のデータによると、2022年にFDAが承認した個別化医薬品は、新たに開発された医薬品の34%にあたる。この動向は過去8年間一貫しており、新薬の少なくとも25%が個別化医薬品として承認されています。その結果、個別化医療に対する需要の高まりが、アントラサイクリン市場拡大の原動力となっています。

アジア太平洋地域は、2023年のアントラサイクリン市場において最大の地域でした。アントラサイクリンレポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のアントラサイクリン市場、医薬品別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • ダウノルビシン
  • ドキソルビシン
  • エピルビシン
  • イダルビシン
  • ミトキサントロン
  • バルルビシン
  • 世界のアントラサイクリン市場、用量別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 粉末
  • カプセル
  • 溶液
  • 注射
  • 懸濁液
  • その他の用量
  • 世界のアントラサイクリン市場、用途別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 急性リンパ性白血病
  • 急性骨髄性白血病
  • ホジキンリンパ腫
  • 非ホジキンリンパ腫
  • 膀胱がん
  • 乳がん
  • その他の転移性がん
  • 世界のアントラサイクリン市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院
  • ホームケア
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のアントラサイクリン市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のアントラサイクリン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • アントラサイクリン市場の競合情勢
  • アントラサイクリン市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Fresenius SE &Co. KGaA

第31章 その他の主要および革新的な企業

  • Merck & Co. Inc.
  • Gilead Sciences Inc.
  • Zydus Lifesciences Limited
  • Viatris Inc.
  • Baxter International Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Limited
  • Jazz Pharmaceuticals Inc.
  • Gland Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals PLC
  • Endo Pharmaceuticals Inc.
  • Amneal Pharmaceuticals Inc.
  • Zhejiang Hisun Pharmaceutical Co. Ltd.
  • Accord Healthcare Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12260

“Anthracycline Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anthracycline market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anthracycline? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The anthracycline market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drugs: Daunorubicin; Doxorubicin; Epirubicin; Idarubicin; Mitoxantrone; Valrubicin
  • 2) By Dosage: Powder; Capsule; Solution; Injection; Suspension; Other Dosages
  • 3) By Application: Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Bladder Cancer; Breast Cancer; Other Metastatic Cancers
  • 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Novartis AG; Bristol-Myers Squibb Company; Fresenius SE & Co. KGaA
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Anthracyclines represent a class of potent chemotherapy drugs derived from specific Streptomyces bacteria strains. These drugs exert their therapeutic action by disrupting the DNA (deoxyribonucleic acid) within cancer cells, effectively impeding their growth and replication. Anthracyclines find application in the treatment of a range of cancer types, including but not limited to breast cancer, various lymphomas, leukemia, and more.

The primary anthracycline drugs encompass daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin. Daunorubicin, for instance, serves as an anthracycline chemotherapy agent that operates by hindering the synthesis of both DNA and RNA. This inhibition is achieved through the intercalation of daunorubicin into the DNA helix, coupled with the inhibition of topoisomerase II. This dual mechanism results in cell cycle arrest and the induction of apoptosis, particularly in rapidly dividing cells. Anthracycline drugs are available in various formulations, including powders, capsules, solutions, injections, suspensions, and others. These formulations serve multiple therapeutic applications, addressing conditions such as acute lymphocytic leukemia, acute myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, bladder cancer, breast cancer, and more. The diverse array of end users for these medications includes hospitals, home care settings, specialty clinics, and others.

The anthracycline market research report is one of a series of new reports from The Business Research Company that provides anthracycline market statistics, including anthracycline industry global market size, regional shares, competitors with an anthracycline market share, detailed anthracycline market segments, market trends and opportunities and any further data you may need to thrive in the anthracycline industry. This anthracycline market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthracycline market size has grown strongly in recent years. It will grow from $1.41 billion in 2023 to $1.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising prevalence of cancer, growing demand for personalized cancer treatment, rising awareness of the benefits of anthracyclines, investment in anthracycline .

The anthracycline market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing awareness about cancer treatment, investments in research and development for cancer treatments, growing demand for effective and convenient treatments for cancer, growing number of screening programs for cancer, government initiatives. Major trends in the forecast period include advancements in anthracycline formulations, combination therapies, cardioprotective strategies, developing biosimilars of anthracyclines.

The burgeoning prevalence of cancer is poised to act as a major catalyst for the future growth of the anthracycline market. Cancer, a group of disorders characterized by the unbridled proliferation of abnormal cells that can manifest in virtually any organ or tissue within the body, often transcending their typical boundaries and potentially spreading to other body parts or invading neighboring tissues. In this landscape, anthracyclines, a class of potent chemotherapy drugs, assume a crucial role in cancer treatment. They achieve this by impeding cell division through the disruption of DNA structure, effectively terminating its normal function. For instance, as of 2023, data from the American Cancer Society Inc., a US-based nonprofit health organization, projects a rise in new cancer cases with an estimated 1.9 million diagnoses in the United States. This marks an increase from the 1.8 million new cancer cases diagnosed in 2020. Furthermore, the anticipated figures for cancer-related deaths in 2023 stand at approximately 609,820, compared to the expected 606,520 in 2020. Consequently, the mounting incidence of cancer is the driving force behind the burgeoning anthracycline market.

The anthracycline market is primed for substantial growth in the foreseeable future, primarily attributed to the escalating adoption of personalized medicine. Personalized medicine, often referred to as precision medicine, represents a niche within medical treatment characterized by tailoring therapeutic approaches to the unique attributes of individual patients. This level of customization takes into account the genetic, molecular, and specific disease characteristics of patients, allowing for the precise integration of anthracycline chemotherapy drugs in combination with targeted therapies. The result is the delivery of more effective and less harmful treatment strategies.For instance, as of October 2022, reports from STAT, a US-based health-focused news entity, revealed that there are in excess of 75,000 genetic testing products and 300 personalized medicines in existence. Furthermore, data from the Personalized Medicine Coalition, a representative organization based in the United States, indicated that in 2022, the FDA approved personalized medicines for 34% of newly developed drugs. This trend has been consistent over the preceding eight years, with at least 25% of new drugs receiving approval as personalized medicines. Consequently, the escalating demand for personalized medicine stands as the driving force behind the expansion of the anthracycline market.

The growth of the anthracycline market faces hindrance during the forecast period due to the notable side effects associated with anthracycline use. Side effects serve as a substantial deterrent in the administration of anthracycline drugs, effectively diminishing the demand for these treatments. This limitation results in a reduction in available therapeutic options, often causing patient discomfort and non-adherence to treatment regimens. For instance, as of 2023, data from the National Library of Medicine, a US-based biomedical library, underscores the various side effects that anthracycline treatments can induce. These include symptoms such as chills, urticaria, pruritus, rashes, and heightened susceptibility to infections. In light of these side effects, the growth of the anthracycline market is notably impeded.

In the realm of anthracycline market dynamics, major companies are actively pursuing innovative drug developments, exemplified by products like Doxorubicin Liposome Injection, to solidify their market presence. For instance, in October 2021, Padagis LLC, an Israel-based pharmaceutical enterprise specializing in the production of generic prescription medications, made headlines with the FDA's (Food and Drug Administration) approval and launch of a generic rendition of Doxil, known as Doxorubicin Liposome Injection. This milestone marked the drug's introduction with an AB rating and came to fruition through a strategic collaboration with Ayana Pharma Ltd., an Israeli entity renowned for its development of liposomal drugs tailored for cancer therapeutics. Doxil Liposome Injection, classified as an anthracycline topoisomerase inhibitor, finds application in treating conditions such as ovarian cancer, Kaposi's sarcoma associated with AIDS (acquired immunodeficiency syndrome), and multiple myeloma. Its mode of action revolves around the inhibition or deceleration of cancer cell proliferation. Administration is achieved through intravenous injection, a process lasting 30 to 60 minutes or potentially longer. This example illustrates how innovative drug development and the production of generic alternatives are reshaping the anthracycline market.

In March 2021, Altaris Capital Partners LLC, a private equity firm headquartered in Denmark with a specialization in medical product investments, completed the acquisition of Padagis LLC from Perrigo Company PLC for a transaction valued at $1.55 billion. This strategic acquisition served as a means for Altaris Capital Partners LLC to broaden its portfolio in the realm of generic pharmaceutical products. Additionally, it facilitated access to the extensive expertise and resources held by Padagis LLC. Notably, Padagis LLC, headquartered in Israel, is a pharmaceutical company renowned for its production of generic anthracycline medications.

Major players in the anthracycline market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Merck & Co. Inc., Gilead Sciences Inc., Zydus Lifesciences Limited, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Gland Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Accord Healthcare Limited, Athenex Inc., Miracalus Pharma Pvt. Ltd, Transo-Pharm Usa LLC, BluePoint Laboratories, Areva Pharmaceuticals Inc., GeneraMedix Inc., Salius Pharma Pvt. Ltd.

Asia-Pacific was the largest region in the anthracycline market in 2023. The regions covered in anthracycline report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anthracycline market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The anthracycline market consists of sales of aclarubicin and pixantrone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Anthracycline Market Characteristics

3. Anthracycline Market Trends And Strategies

4. Anthracycline Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Anthracycline Market Size and Growth

  • 5.1. Global Anthracycline Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Anthracycline Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Anthracycline Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Anthracycline Market Segmentation

  • 6.1. Global Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Daunorubicin
  • Doxorubicin
  • Epirubicin
  • Idarubicin
  • Mitoxantrone
  • Valrubicin
  • 6.2. Global Anthracycline Market, Segmentation By Dosage, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Powder
  • Capsule
  • Solution
  • Injection
  • Suspension
  • Other Dosages
  • 6.3. Global Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Hodgkin's Lymphoma
  • Non-Hodgkin's Lymphoma
  • Bladder Cancer
  • Breast Cancer
  • Other Metastatic Cancers
  • 6.4. Global Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users

7. Anthracycline Market Regional And Country Analysis

  • 7.1. Global Anthracycline Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Anthracycline Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Anthracycline Market

  • 8.1. Asia-Pacific Anthracycline Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Anthracycline Market

  • 9.1. China Anthracycline Market Overview
  • 9.2. China Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Anthracycline Market

  • 10.1. India Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Anthracycline Market

  • 11.1. Japan Anthracycline Market Overview
  • 11.2. Japan Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Anthracycline Market

  • 12.1. Australia Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Anthracycline Market

  • 13.1. Indonesia Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Anthracycline Market

  • 14.1. South Korea Anthracycline Market Overview
  • 14.2. South Korea Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Anthracycline Market

  • 15.1. Western Europe Anthracycline Market Overview
  • 15.2. Western Europe Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Anthracycline Market

  • 16.1. UK Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Anthracycline Market

  • 17.1. Germany Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Anthracycline Market

  • 18.1. France Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Anthracycline Market

  • 19.1. Italy Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Anthracycline Market

  • 20.1. Spain Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Anthracycline Market

  • 21.1. Eastern Europe Anthracycline Market Overview
  • 21.2. Eastern Europe Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Anthracycline Market

  • 22.1. Russia Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Anthracycline Market

  • 23.1. North America Anthracycline Market Overview
  • 23.2. North America Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Anthracycline Market

  • 24.1. USA Anthracycline Market Overview
  • 24.2. USA Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Anthracycline Market

  • 25.1. Canada Anthracycline Market Overview
  • 25.2. Canada Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Anthracycline Market

  • 26.1. South America Anthracycline Market Overview
  • 26.2. South America Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Anthracycline Market

  • 27.1. Brazil Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Anthracycline Market

  • 28.1. Middle East Anthracycline Market Overview
  • 28.2. Middle East Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Anthracycline Market

  • 29.1. Africa Anthracycline Market Overview
  • 29.2. Africa Anthracycline Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Anthracycline Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Anthracycline Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Anthracycline Market Competitive Landscape And Company Profiles

  • 30.1. Anthracycline Market Competitive Landscape
  • 30.2. Anthracycline Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bristol-Myers Squibb Company
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Fresenius SE & Co. KGaA
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Anthracycline Market Other Major And Innovative Companies

  • 31.1. Merck & Co. Inc.
  • 31.2. Gilead Sciences Inc.
  • 31.3. Zydus Lifesciences Limited
  • 31.4. Viatris Inc.
  • 31.5. Baxter International Inc.
  • 31.6. Teva Pharmaceutical Industries Ltd.
  • 31.7. Sun Pharmaceutical Industries Limited
  • 31.8. Jazz Pharmaceuticals Inc.
  • 31.9. Gland Pharma Limited
  • 31.10. Dr. Reddy's Laboratories Ltd.
  • 31.11. Hikma Pharmaceuticals PLC
  • 31.12. Endo Pharmaceuticals Inc.
  • 31.13. Amneal Pharmaceuticals Inc.
  • 31.14. Zhejiang Hisun Pharmaceutical Co. Ltd.
  • 31.15. Accord Healthcare Limited

32. Global Anthracycline Market Competitive Benchmarking

33. Global Anthracycline Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Anthracycline Market

35. Anthracycline Market Future Outlook and Potential Analysis

  • 35.1 Anthracycline Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Anthracycline Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Anthracycline Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer